СцембліксАсцімініб40 mg60 табТатЛаос Indication \r\n Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors.6,9 It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.6 \r\n \r\n The drug is also indicated under accelerated approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors.6,9 It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.6
The drug is also indicated under accelerated approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
